research centers


Search results: Found 19

Listing 1 - 10 of 19 << page
of 2
>>
Sort by

Article
Assessment of cytogenetic response after treatment with imatinib mesylate in patients with chronic phase chronic myeloid leukemia

Author: Alaa Fadhil Alwan
Journal: Iraq Joural of Hematology المجلة العراقية لامراض الدم ISSN: 20728069/25432702 Year: 2014 Volume: 3 Issue: 1 Pages: 56-61
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder affecting hematopoietic stem cells andaffects predominantly granulocyte progenitor line. It is characterized by acquired chromosomal abnormality which calledthe Philadelphia chromosome (Ph+) in 95% of cases. Imatinib mesylate is a powerful and selective competitive inhibitorof BCR-ABL tyrosine kinase. Imatinib mesylate is the first molecular target therapy for the treatment of CMLObjectives: The aim of this study was to evaluate the cytogenetic response in 58 patients with CML in chronic phasetreated with imatinib mesylate.Materials and methods: A prospective study conducted at the national center of hematology /Almustansiriya University,Baghdad, Iraq from April 2011 to December 2013, fifty-eight patients with CML in chronic phase (32 male and 26female) were enrolled in this study. All patients were carrying the BCR-ABL fusion gene and treated with Imatinibmesylate (Glivic® Novartis) at 400 mg daily for at least 12 monthsResults: There were 32 male and 26 female with male to female ratio (1.1:1).the median age was 36 year (range 14-64years). The median duration of treatment with imatinib was 18 months (range 12 to 32 months). Complete hematologicresponses (CHR) were attained in 54 of 58 (93%) patients treated during the first 3 months of imatinib therapy, where 11(19%) of patients reached CHR after 1 month, 35 (60%) got CHR within 2 months of treatment with imatinib.Cytogenetic response rates to imatinib therapy at 6 and 12months. : Major cytogenetic response achieved in 35 (70%), 48(92.3%) patients and minor cytogenetic response attained in 15 (30%), 4 (7.7%) patient at 6, 12 month respectively.Imatinib was usually safe and well tolerated. The vast majority of adverse effects were grade 1 and 2 and bone pain wasthe most common (86.2%).Conclusion: After a median follow-up of 18 months, this study confirm that imatinib therapy induced induce durableand sustained hematological and cytogenetic responses in a high proportion of patients with chronic-phase CML. theresponse rates of imatinib therapy were similar to those reported in other countries. Imatinib was safe and well-toleratedwith manageable side effects.

Keywords

cytogenetic response --- imatinib --- CML


Article
Changes of immunological, Cytogenetic & Hematological Profiles in Chronic Myeloid Leukemia Treated with Imatinib Mesylate

Author: Almotessembellah Abdalruhman
Journal: Iraq Joural of Hematology المجلة العراقية لامراض الدم ISSN: 20728069/25432702 Year: 2014 Volume: 3 Issue: 1 Pages: 35-42
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Background: Chronic myeloid leukemia (CML) (also known as chronic myelogenous leukemia, chronic granulocyticleukemia) is a clonal disease that results from an acquired genetic change in a pluripotential hemopoietic stemcell .Imatinib mesylate, is an inhibitor of the family of ABL kinases, these proteins serves a complex role in cellcycling and is important in lymphopoiesis, and has been shown to have impressive clinical activity in chronicmyeloid leukemiaObjectives: to assess the immunological, cytogenetic, and hematological parameters in patients with chronic myeloidleukemia on imatinib therapyMaterial and methods: Thirty one CML patients treated with imatinib mesylate at standard dosage were enrolled inthis prospective study. All patients were seen in the Department of hematology at the national center ofhematology /Almustansiriya University for six months from February to July 2012.Data on blood cell counts andblood film, serum levels of IgG, IgA ,IgM ,C3 and C4;assessed by radial immundiffusion method,Results: Twenty four out of thirty one CML patients treated with the imatinib regimen (those had done FISH study)reached a complete cytogenetic response. Reduction percent were 19.35% for IgG, 16.13% for IgM and 9.68%for IgA, six patients had IgG inferior to normal laboratory range, five patients presented a reduction of IgM andthree patients had IgA lower than normal range. No significant correlation of immunoglobulin levels compared toduration of treatmentConclusion: Imatinib mesylate can induce complete cytogenetic response in a high percent of CML patients. Cytogeneticresponse correlates well with duration of treatment .there is insignificant reduction of immunoglobulins levelspecially IgM. There is disturbance in the serum level of complement components (C3 &C4).There isinsignificant reduction in the absolute count of lymphocytes in correlation with duration of treatment


Article
Hematological events and thyroid status in Imatinib treated CML Iraqi
التأثيرات الجانبيه وحاله الغده الدرقيه في مرضى أبيضان الدم المزمن الحبيبي العراقيين تحت علاج ايماتنب

Author: Khaleed J. Khaleel خالد جمعه خليل
Journal: Iraqi Journal of Cancer and Medical Genetics المجلة العراقية للسرطان والوراثة الطبية ISSN: 20786123 Year: 2016 Volume: 9 Issue: 2 Pages: 133-137
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Background: Chronic myeloid leukemia (CML) is myeloproliferative of hematopoietic stem cells resulting in marked in- creased in granulocytes, platelets and red cells.Imatinib mesylate (IM) is potent tyrosine kinase inhibitor acts by occupying ATP binding site for BCR-ABL oncoprotein pre- venting phosphorylation of substrate and interrupting contact with protein.Aim of study: Evaluation of thyroid function and myelosuppresion induced by IM in CML patients.Materials and Methods: The study enrolled 13 patients with CML treated by IM for more than 6 months. Total blood count and blood lm and thyroid function.Tests (T1 ,T4 and TSH) were performed.Results: All patients belong to Grade3 and Grade2 only of mylosuppresion, the most common cytopenia is neutropenia in (7) patients, anemia in (5) patients and only (4)patients having thrombocytopenia. Only three patients don’t achieve remission (6.6 %).Regarding thyroid function only one patient has high TSH level with normal T1 and T4. In spite of TSH level in patients signi cantly higher than the control group the mean values of two group were within normal range. Non-signi cant difference in T1 and T4 between the control and patients groups.Conclusion: IM do not seem to has clinically signi cant effect on thyroid function. However, thyroid function test is indicated before initiated of treatment with IM. Also CBC is highly recommended for monitoring CML patients on IM.

ان مرض أبيضان الدم الحبيبي المزمن هو اضطراب الخ يا الجذعية الدمويه مما ينتج عنها زياده كبيره في كريات البيض الحبيبيه وأقراص الدم والكريات الحمراء،يعتبر عقار ايماتنب ماسيليت مثبط فعال نزيم تايروسين كاينيز وذلك من خ ل منع جزءيه ATP من ا لتصاق بالبروتين المسرطن واكمال عمليه الفسفره . تهدف الدراسه الى تقييم وظائف الغده الدرقيه ومدى تثبيط انتاج خ يا الدم من قبل عقار ايماتنب في مرضى ابيضاض الدم الحبيبي المزمن في العراقيين تضمنت الدراسه )31( مريضامصابين بابيضاض الدم الحبيبي المزمن في حالته المزمنة عولجوا بعقار ايماتنب لمده سته أشهر فاكثر . تم اجراء صوره الدمالكامله وفحوصات وظائف الغده الدرقيه ) T3 , T4 , TSH ( . أظهرت النتائج بان كل المرضى ينتمون الى الدرجه ا ولى والثانيه في مستوى تثبيط انتاج خ يا الدم وا كثر شيوعا )7 ( مرضى ماتصبون بنقص انتاجكريات الدم البيض الحبيبه و خمس مرضى بفقر الدم وأربع مرضى يعانون من نقص في ا قراص الدمويه .وهنالك ث ث مرضى فقط )%9.6( لم يصلو بعد الى مستوى ا فاقه من المرض.وبخصوص الغده الدرقيه تبين وجود مريض واحد فقط لديه )TSH( فوق المستوى الطبيعي مع مستوى طبيعي لكل من T4 و T3. وجد هنالك فارق معنوي اعلى في TSHفي مجموعه المرضى مقارنه بمجموعه السيطره ولكن المعدل ضمن الحدود الطبيعية للفحص. تبين ان عقار ايماتنب يؤثر سريريا على وظائف الغده الدرقيه ومع ذلك ينصح بإجراء فحوصات الغده الدرقيه قبل البدء بالع ج وكذلك صوره الدم مهمهجدا في مراقبه المريض اثناء الع ج


Article
Survival of Patients with CML on Imatinib Experience with 44 IraqiPatients

Authors: Nabeel Salman --- Batool A.G. Yassin --- Ali M.Jawad
Journal: Journal of the Faculty of Medicine مجلة كلية الطب ISSN: PISSN: 00419419 / EISSN: 24108057 Year: 2008 Volume: 50 Issue: 3 Pages: 286-295
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Background: Chronic myeloid leukemia (CML) is a clonal stem disease with distinctive
clinical course which is ultimately fatal. It is characterized by the presence of Philadelphia
chromosome (t 9:22).Tyrosine kinase inhibitors like imatinib mesylate as targeted therapy had
revolutionized the management of CML with significant prolongation of overall survival and
decreased rate of blastic transformation.
Objective:This study will describe the experience of treating 44 Iraqi patients with chronic
myeloid leukemia by imatinib at the National Hematology Centre in Baghdad.
Patients and Methods:This study included 44 Iraqi patients diagnosed in Chronic phase CML
at the National Centre of Hematology in Baghdad from February 2003 till January 2006, all
were pretreated with alfa interferon and hydroxyurea. All patients were started on imatinib
mesylate 400 mg orally daily. The end points included overall survival (OS) and Blastic
transformation free survival (TFS).The effect of age, gender, WBC count on starting Imatinib,
presence of splenomegaly and duration of diagnosis of CML prior to starting imatinib, on the
OS and TFS were studied.
Results:Median age was 35 years with 27 males and 17 females. The 3 year OS was 88.6%
and the TFS was 79.5%.The only factor that had negative impact on OS and TFS was a
diagnosis of CML more than 2 years before starting imatinib. The most common side effects
were myalgia(75%) and peripheral oedema(65%). Neutropenia(20%),thrombocytopenia(12%)
and elevated serum transaminases (2%) necessitated temporary cessation of treatment.No
cytogenetic and molecular studies were available .
Conclusion:Imatinib is an effective therapy for Iraqi patients with CML with tolerable side
effects and should be offered to newly dignosed CML patients as early as possible as frontline
therapy to ensure better OS and TFS.Establishment of cytogenetic and molecular studies are
crucial to optimize management.


Article
Molecular assessment of apoptotic genes in leukemic patients
التقييم الجزيئي لجينات الموت الخلوي المبرمج لدى مرضى لوكيميا ابيضاض الدم

Authors: ندى محمد سعدون --- كريم حمد غالي
Journal: Journal Of Wassit For Science & Medicine مجلة واسط للعلوم والطب ISSN: 58161992 Year: 2015 Volume: 8 Issue: 1 Pages: 105-114
Publisher: Wassit University جامعة واسط

Loading...
Loading...
Abstract

AbstractLeukemia is one of the commonest ten cancers in Iraq and worldwide. This disease is classified into myeloid or lymphoid and they are further divided into chronic or acute leukemia. This research included chronic myeloid leukemia (CML) in fourty nine patients (22males and 27females).Multiplex polymerase chain reaction was done to analyze five human apoptotic genes (P53,Bcl2,Cmyc,ICE and GAPDH).These genes demonstrated highly significant comparing with ten control p<0.05(p=0.000, p=0.000, p=0.000, p=0.004) GAPDH regarded as internal control. While they didn’t show any significance with gender, age groups or phases except P53 was showed highly significant with blast transformation phase. These results showed that genes were expressed in patients, and these may regard as important indicators for this disease. Further studies are needed to confirm this observation and better elucidate the mechanism. The aim of this research is to study the molecular expression of apoptotic genes in leukemic patients compared with healthy controls and study the expression of apoptotic genes in leukemic patients related to gender, age groups and phases of CML.

المستخلص تعتبر اللوكيميا واحدة من السرطانات العشرة الشائعة في العراق والعالم,وهو مرض خبيث يصيب الأنسجة المكونة للدم كنخاع العظم والنسيج اللمفاوي.تصنف اللوكيميا الى نقوية ولمفاوية والتي تنقسم بدورها الى قسمين حادة ومزمنة. تضمنت الدراسة الحالية النوع النقوي المزمن لدى تسعة واربعون مريضا(22ّذكورا و27أناثا)وقد تم استخدام تقنية تفاعل البلمرة المتسلسل المتعدد لخمسة من جينات الموت الخلوي المبرمج P53,Bcl2,Cmyc,ICE) و(GAPDH لدى هؤلاء المرضى. وقد اضهرت هذه الجينات تعبيرا معنويا موجبا في العينة المرضية مقارنة بعينة السيطرة التي شملت عشرة أشخاص أصحاء p<0.05(p=0.000, p=0.000, p=0.000, p=0.004). . على أعتبار أن الجين GAPDH هو جين سيطرة.في حين لم تظهر هذه الجينات اي علاقة معنوية مع الجنس او العمر او الطور المرضي ماعد الجينP53 الذي اظهر علاقة معنوية عالية مع الطور الأرومي. أشارت هذه النتائج بشكل واضح ان جينات الموت الخلوي المبرمج قد اظهرت تعبيرا في المرضى بنسب مختلفة نتيجة الاصابة بالمرض ويمكن استخدامها كدلالات مهمة في تشخيص المرض.ومع ذلك نحتاج الى دراسات اخرى لتاكيد هذه النتائج .الهدف من هذا البحث هو دراسة التعبير الجيني لجينات الموت الخلوي المبرمج لدى مرضى اللوكيميا مقارنة مع مجموعة السيطرة وكذلك دراسة التعبير الجيني للجينات المذكورة وعلاقتها بالمتغيرات الأكلينيكية كالجنس ,المجاميع العمرية والأطوار المرضية لدى مرضى اللوكيميا النقوية المزمنة.


Article
Influence of multi-drug transporter gene ABCG2 polymorphism (C421A) in clinical out care in some Iraqi chronic myeloid leukemia patients treated with imatinib mesylate

Loading...
Loading...
Abstract

In CML patients, Imatinib Mesylate (IM) treatment is a good choice with an excellent efficacy outcome. But unfortunately, a significant obstacle of IM resistance has emerged relating to the genetic polymorphism in drug transporter genes such as ABCG2 which effects the metabolism and pharmacokinetic IM. This study investigate the influence of ABCG2 C421A SNP in IM response among some Iraqi CML Patients (71 patients : 43 Male , 28 Female) aged between ( 20-70 ) years in chronic phase with positive Philadelphia (Ph) chromosome, including 11 newly diagnosed , and 60 treated with standard dose IM (400mg) on frontline treatment , 30 of them were IM response and 30 resistance to IM drug , on the other hand 25 apparently healthy individuals were included as control group. After the patients were informed about the details of the research, they were approved to take samples of their blood for study , 3ml of peripheral blood was withdrawn from CML patients and control groups . The frequency of homozygous mutant genotype (AA) of SNPabcg2 C421Awas significant higher in IM resistant CML patients as compared to IM good response CML patients with (O.R=1.309 and p < 0.01) . The SNP abcg2 C421A was found to contribute to the genetic susceptibility of CML when evaluated with healthy control subjects. These reconnoitering results give a reasonable cause to explore such SNPs to be used as a biomarker in prediction the response to IM treatment before getting started.


Article
Molecular diagnosis of bcr-abl fusion gene in CML patients using Multiplex-Reverse Transcreptase-Polymerase Chain Reaction
الكشف الوراثي الجزيئي لجين BCR-ABL في مرضى ابيضاض الدم النخاعيني المزمن باستخدام تقنية تفاعل الاستنساخ الرجعي لجينات متعددة – التفاعل المتسلسل لانزيم بلمرة الدنا

Author: Maysaa Abdul Razaq Dhahii د. ميساء عبد الرزاق ضاحي
Journal: IRAQI JOURNALOF COMMUNITY MEDICINE المجلة العراقية لطب المجتمع ISSN: 16845382 Year: 2010 Volume: 23 Issue: 3 Pages: 141-146
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Background: Chronic myeloid leukemia (CML) is a stem cell disorder results from chromosomal abnormality, Philadelphia chromosome (Ph), which arises from the reciprocal translocation of part of long arm of chromosome 9, in which proto-oncogene ABL gene (ablson) is located, to long arm of chromosome 22, in which BCR gene (break point cluster region) is located forming BCR-ABL fusion gene, a molecular marker of CML. The BCR-ABL gene can be detected using several molecular methods, including southern blotting, fluorescence in situ hybridization (FISH) and Reverse Transcreptase-Polymerase Chain Reaction (RT-PCR). For its simplicity, rapidity, and sensitivity, RT-PCR is one of the most common techniques used for analyzing whether a target gene is being expressed or not. Objective: This study was designed as a try to apply molecular techniques as conformational diagnosis of BCR-ABL gene and its variants in CML patients. Patients & Methods: Venous blood sample from 34 CML patients, 12 ALL patients, 1 AML patients, 1 CMML patient and 2 healthy individuals were collected. RNA was extracted from these samples using specific kit for this purpose. Molecular screening for the presence of bcr-abl in those samples was done using Multiplex-Single Step-Reverse Transcriptase-Polymerase Chain Reaction (M-SS-RT-PCR). Amplified products were electrophoresid in 1.5% agarose gel. Results: The results showed that all CML patients were positive for bcr-abl while all the others were negative for this gene. Conclusion: qualitative molecular diagnosis of bcr-abl using M-SS-RT-PCR considered as Conformational diagnosis for CML patients before starting treatment.Key Word: CML - BCR/ABL -Multiplex Reverse Transcreptase Polymerase Chain Reaction.

خلفية الدراسة:سرطان الدم المايلودي المزمن ناجم عن اختلال كروموسومي كروموسوم فيلادلفيا والناجم عن انقلاب غير توافقي في جزء من الذراع الطويل للكروموسوم رقم 9 وفيها البوتوجين يسقط فوق الذراع الطويل للكروموسوم رقم 22 وهناك علامات وجود مؤشر جزيئي لسرطان الدم المايلويدي. هذه الاصابة في الجين ممكن كشفه بعدة طرق اسهلها هو باسعمالتفاعل السلسلة البوليمريه أهداف الدراسة:طريقه سريعه وخفيفه للكشف عن الجين الجزيئي المصاب ب(RT-PCR) وتشخيص سرطان الدم المايلودي المزمنطريقة العمل:تم جمع عينات من دم المرضى المصابين بسرطان الدم سرطان الدم المايلودي المزمن34و, سرطان الدم اللمفاوي12 الحاد, سرطان الدم المايلويدي الحاد 1 الميلوما المتعدد 1 واثنا اصحاء. تم استخلاص الحمض النووي RNA باستعمال الطريقة الجديدة للكشف عن الجين وفحص جميع العينات النتائج:ان جميع المصابين بسرطان الدم المايلويدي المزمن كان موجبي الفحص باستعمال PCRبينما جميع المرضى الاخرين والاصحاء كانت سالبهالاستنتاجات:استعمال الطريقة الجديدة هي الامثل لتشخيص المرض قبل البدء بالعلاج


Article
Relationship between CML and Io's phase according to Jupiter's actual radio storms observations
العلاقة بين خط الطول المركزي وطور القمر ايو حسب الارصادات الحقيقية للعواصف الراديوية

Authors: Rasha H. Ibrahim رشا هاشم إبراهيم --- Kamal M.Abood كمال محمد عبود
Journal: Iraqi Journal of Physics المجلة العراقية للفيزياء ISSN: 20704003 Year: 2013 Volume: 11 Issue: 20 Pages: 100-109
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

The actual observations for Jupiter radio storm were taken for Hawaii station within multi years from 2001 to 2012. The Central Meridian Longitude (CMLІІІ) and Io's phase (γIo) were calculated for each year from Radio Jove program, the results of CMLІІІ for year 2006 was A=(180-300)º,B=(15-239)º, C=(60-280)º, phase was A=(182-260)º,B=(40-109)º, C=(200-260)º, which were close to the theoretical values, longitude was A=(180-300)º, B=(15-240)º, C=(60-280)º and phase was A=(180-260)º,B=(40-110)º and C=(200-260)º.

أخذت الارصادات الحقيقية للعواصف الراديوية من كوكب المشتري لموقع هاوي خلال عدة سنوات من سنة (2001-2012), حسب خط الطول المركزي وطور القمر ايو لكل سنة من برنامج الراديو جوفا , كانت نتائج خط الطول للعواصف الراديوية لسنة=A 2006 (180-300 (و=B (15- (239و=C (60- 280) الطور=A (182-260) و=B (40-109 ) و=C (200- 260) وكانت قريبة للنتائج النظرية , خط الطول =A (180-300 ) و=B (15- (240 و =C ( 60-280 ( والطور=A (180-260) و=B (40-110) و =C(60- .(260


Article
The Study of Inhibitory Effects of Some Plant Extracts on Lymphocytes from Healthy Person
دراسة التأثیر التثبیطي لبعض المستخلصات النباتیة على الخلایا اللمفاویة لاشخاص اصحاء

Authors: Azhar M. Haleem ازھار محمود حلیم --- Esmaeel K. Shubber اسماعیل كاظم شبر --- Abdul Wahid B. Al-Shaibani عبد الواحد باقر
Journal: Engineering and Technology Journal مجلة الهندسة والتكنولوجيا ISSN: 16816900 24120758 Year: 2013 Volume: 31 Issue: 6 Part (B) Scientific Pages: 139-155
Publisher: University of Technology الجامعة التكنولوجية

Loading...
Loading...
Abstract

The present study aimed to select plant extract or mix. of plant extracts have inhibition effect on Cancer cells from untreated CML patients the results showed the following.Some plants extracts were used (aqueous, alcoholic, oily, alkaloid and flavonoids) from Nigella sativa seeds, Allium sativum Sativum and Allium sativum ophioscordon fruits and the inhibitory effects five different concentrations (0.1,1,10,10,1000) µg/ml was investigated on peripheral lymphocytes from healthy persons by using cytogenetic analysis BI,MI,RI,CA,SCE and CCP. The alcoholism mix. have the greatest inhibitory effects by reducing all cytogenetic parameters, this was selected to study its effect on patient’s lymphocytes.

تهدف الدراسة الحالية الى انتخاب مستخلص نباتي او مزيج من المستخلصات النباتية له تأثير تثبيطي في خلايا لمفاوية لاشخاص بايضاض الدم النخاعيني المزمن، كخطوة تمهيدية وباستخدام مجموعة من طرائق الاستخلاص المختلفة ( المائي، الكحولي، الزيتي، المزيج المائي، المزيج الكحولي، الالكلويدي والفلافينويدي)لبذور نبات حبة البركة Nigella sativaوثمار نباتي الثوم و Allium sativum sativum الصرماق Allium sativum ophioscordon، باستخدام خمسة تراكيز هي ( 0.1، 1،10، 100، 1000) مكغم/ مل . تم اختيار التركيز الامثل والمستخلص الامثل والذي يعطي اكبر نسبة تثبيط لمؤشرات التحليلات الوراثية كعامل لتحول الارومي ومعامل الانقسام الخيطي ومعامل الزيغ الكروموسومي والتبادل الكروماتيدي الشقيق ومعامل التضاعف وتوالي دورة الخلية . اشارت النتائج الى ان مزيج المستخلصات الكحولية للنباتات الثلاثة اعطى اعلى نسبة تثبيط للمؤشرات السابقة ليتم انتخابه لدراسة تأثيره على خلايا لمفاوية من مرضى ابيضاض الدم النخاعيني المزمن.


Article
Molecular diagnosis of bcr-abl fusion gene in CML patients using Monoplex-Two Steps- Reveres Transcriptase–Polymerase Chain Reaction

Author: Maysaa A. Dhahii ميساءعبد الرزاق
Journal: Journal of the Faculty of Medicine مجلة كلية الطب ISSN: PISSN: 00419419 / EISSN: 24108057 Year: 2010 Volume: 52 Issue: 1 Pages: 66-70
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Background: Chronic myeloid leukemia (CML) is a stem cell disorder associated with an acquired chromosomal abnormality, Philadelphia chromosome (Ph), which arises from the reciprocal translocation of part of long arm of chromosome 9, in which proto-oncogene ablson gene (abl) is located, to long arm of chromosome 22, in which break point cluster region gene (bcr) is located. The bcr-abl fusion gene can be detected using several molecular methods. For its simplicity, rapidity, and sensitivity, Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) is one of the most common techniques used for analyzing whether a target gene is being expressed or not.Patients and methods: Venous blood (VB) sample from hematologically and clinically diagnosed 34 CML patients and10 acute lymphoid leukemia (ALL) were collected. Also, 10 healthy individuals were included as health negative control. RNA was extracted from these samples using commercial kit. Molecular screening for the presence of bcr-abl in these samples was done using Monoplex- Two Steps-Reverse Transcriptase-Polymerase Chain Reaction (M-TS-RT-PCR). Amplified products were electrophoresid in 1.5% agarose gel.Results: The results showed that all CML patients were positive for bcr-abl while all the others were negative for this gene. Conclusion: Monoplex - Two steps – RT-PCR has been successfully used to detect and subtype bcr-abl fusion gene. It is a fast and effective technique that should be done upfront at diagnosis in patients with CML, as its molecular type is crucial in the treatment follow-ups.Key words: CML- bcr-abl detection- monoplex- two steps – RT-PCR

Listing 1 - 10 of 19 << page
of 2
>>
Sort by
Narrow your search

Resource type

article (19)


Language

English (16)

Arabic (1)

Arabic and English (1)


Year
From To Submit

2018 (1)

2017 (1)

2016 (3)

2015 (2)

2014 (3)

More...